Adverum Biotechnologies (ADVM) Stock Forecast & Price Target

$7.67

+0.23 (+3.09%)

(As of 12:15 PM ET)

Adverum Biotechnologies - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 6 Analyst Ratings

Sell
0

Hold
1

Buy
5

Based on 6 Wall Street analysts who have issued ratings for Adverum Biotechnologies in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 1 has given a hold rating, and 5 have given a buy rating for ADVM.

Consensus Price Target

$28.17
267.23% Upside

According to the 6 analysts' twelve-month price targets for Adverum Biotechnologies, the average price target is $28.17. The highest price target for ADVM is $40.00, while the lowest price target for ADVM is $12.00. The average price target represents a forecasted upside of 267.23% from the current price of $7.67.

Get the Latest News and Ratings for ADVM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Adverum Biotechnologies and its competitors.

ADVM Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$28.17	$28.17	$28.20	$37.50
Forecasted Upside	267.23% Upside	316.67% Upside	262.47% Upside	271.29% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

U.S. Stock Market Now on Verge of Collapse (Ad)

"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He says what's coming next to the U.S. economy could be much worse than anything he's predicted before. And this time, he says, "The trouble is coming straight for Nvidia and the AI market."

Click here to see why.

ADVM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ADVM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Adverum Biotechnologies Stock vs. The Competition

Type	Adverum Biotechnologies	Medical Companies	S&P 500
Consensus Rating Score	2.83	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	278.58% Upside	10,674.30% Upside	8.03% Upside
News Sentiment Rating	Positive News See Recent ADVM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/14/2024	Truist Financial 2 of 5 stars		Lower Target	Buy ➝ Buy	$60.00 ➝ $40.00	+496.12%
8/13/2024	HC Wainwright 2 of 5 stars	M. Caufield Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00	+345.76%
8/13/2024	Royal Bank of Canada 4 of 5 stars		Lower Target	Sector Perform ➝ Sector Perform	$15.00 ➝ $12.00	+77.25%
7/18/2024	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$4.00 ➝ $40.00	+321.94%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$25.00	+265.50%
4/29/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$40.00 ➝ $22.00	+139.39%
3/7/2023	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$20.00	+161.06%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:43 PM ET.

ADVM Forecast - Frequently Asked Questions

: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Adverum Biotechnologies is $28.17, with a high forecast of $40.00 and a low forecast of $12.00.
: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There is currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ADVM shares.
: According to analysts, Adverum Biotechnologies's stock has a predicted upside of 267.23% based on their 12-month stock forecasts.
: Adverum Biotechnologies has been rated by research analysts at Chardan Capital, HC Wainwright, Royal Bank of Canada, and Truist Financial in the past 90 days.
: Analysts like Adverum Biotechnologies more than other "medical" companies. The consensus rating score for Adverum Biotechnologies is 2.83 while the average consensus rating score for "medical" companies is 2.78. Learn more on how ADVM compares to other companies.